The primary aim of this proposal is to continue the active role that the National Surgical Adjuvant Breast and Bowel Project (NSABP) has had as an NCI-designated research base for the Community Clinical Oncology Project (CCOP). Specifically, the NSABP will: provide breast and colorectal clinical treatment protocols and cancer control research protocols for participating CCOP physicians; provide support services and educational programs for CCOP-related staff; monitor CCOP performance through ongoing quality assurance programs; continue the successful integration of CCOP investigators into the overall functioning of the NSABP. As a CCOP research base since 1983, the NSABP has more CCOP affiliations than any other clinical cooperative group. As a result of their collaboration, the NSABP has accounted for approximately 20% of all CCOP clinical trial treatment accrual and approximately 15% of all subjects entered on cancer control studies over the past three years. Within the NSABP, CCOPs are currently contributing 30% of all adjuvant study accrual. By maintaining this expanded involvement of CCOP physicians in NSABP studies: 1) the benefits of clinical trial participation will continue to be more widely available in the community setting, where over 80% of all cancer patients are treated; 2) answers to the therapeutic questions posed in study protocols will be available more quickly; and 3) a wider segment of the community will be available for research and measurement of advances in cancer control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037377-10
Application #
2089303
Study Section
Special Emphasis Panel (SRC (48))
Project Start
1983-09-15
Project End
1996-05-31
Budget Start
1994-09-01
Budget End
1995-05-31
Support Year
10
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Surgery
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Regan, M M; Walley, B A; Francis, P A et al. (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225-2232
Ternès, Nils; Rotolo, Federico; Michiels, Stefan (2017) Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. BMC Med Res Methodol 17:83
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Ribi, Karin; Bernhard, Jürg; Luo, Weixiu et al. (2016) Reply to F. Tomao et al. J Clin Oncol 34:4189-4190
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Land, Stephanie R; Walcott, Farzana L; Liu, Qing et al. (2016) Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. J Natl Cancer Inst 108:
Ribi, Karin; Luo, Weixiu; Bernhard, Jürg et al. (2016) Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 34:1601-10
Dalerba, Piero; Sahoo, Debashis; Paik, Soonmyung et al. (2016) CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 374:211-22
Johansson, Harriet; Gray, Kathryn P; Pagani, Olivia et al. (2016) Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res 18:110

Showing the most recent 10 out of 239 publications